On August 5, 2024, Kangfang Biotech (Cayman) Limited submitted its latest monthly report on securities changes to Hong Kong Exchanges and Clearing Limited, reporting the company's shareholding changes as of July 31, 2024. The report shows that the company's statutory/registered share capital and issued shares remained unchanged in that month, with a statutory/registered share capital balance of 5,000,000,000 shares, each with a face value of 0.00001 USD, for a total of 50,000 USD. The number of issued shares (excluding treasury shares) remained at 865,857,176 shares. In addition, in the company's stock option plan, the number of stock options for the initial public offering following the adoption on June 28, 2022 remained unchanged at 436,000 this month, and no stock options were exercised this month. The report also indicates that the company has not committed to issuing warrants, convertible bonds, or other changes. The report was submitted by Director Xia Yu.

On August 5, 2024, Kangfang Biotech (Cayman) Limited submitted its latest monthly report on securities changes to Hong Kong Exchanges and Clearing Limited, reporting the company's shareholding changes as of July 31, 2024. The report shows that the company's statutory/registered share capital and issued shares remained unchanged in that month, with a statutory/registered share capital balance of 5,000,000,000 shares, each with a face value of 0.00001 USD, for a total of 50,000 USD. The number of issued shares (excluding treasury shares) remained at 865,857,176 shares. In addition, in the company's stock option plan, the number of stock options for the initial public offering following the adoption on June 28, 2022 remained unchanged at 436,000 this month, and no stock options were exercised this month. The report also indicates that the company has not committed to issuing warrants, convertible bonds, or other changes. The report was submitted by Director Xia Yu.